The impact of family history on non-medullary thyroid cancer

I. J. Nixon, C. Suárez, R. Simo, A. Sanabria, P. Angelos, A. Rinaldo, J. P. Rodrigo, L. P. Kowalski, D. M. Hartl, M. L. Hinni, J. P. Shah, A. Ferlito

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Introduction Around 10% of patients with non-medullary thyroid cancer (NMTC) will have a positive family history for the disease. Although many will be sporadic, families where 3 first-degree relatives are affected can be considered to represent true familial non-medullary thyroid cancer (FNMTC). The genetic basis, impact on clinical and pathological features, and overall effect on prognosis are poorly understood. Methods A literature review identified articles which report on genetic, clinical, therapeutic and screening aspects of FNMTC. The results are presented to allow an understanding of the genetic basis and the impact on clinical–pathological features and prognosis in order to inform clinical decision making. Results The genetic basis of FNMTC is unknown. Despite this, significant progress has been made in identifying potential susceptibility genes. The lack of a test for FNMTC has led to a clinical definition requiring a minimum of 3 first-degree relatives to be diagnosed with NMTC. Although some have shown an association with multi-centric disease, younger age and increased rates of extra-thyroidal extension and nodal metastases, these findings are not supported by all. The impact of FNMTC is unclear with all groups reporting good outcome, and some finding an association with more aggressive disease. The role of screening remains controversial. Conclusion FNMTC is rare but can be diagnosed clinically. Its impact on prognostic factors and the subsequent role in influencing management is debated. For those patients who present with otherwise low-risk differentiated thyroid cancer, FNMTC should be included in risk assessment when discussing therapeutic options.

Original languageEnglish (US)
Pages (from-to)1455-1463
Number of pages9
JournalEuropean Journal of Surgical Oncology
Volume42
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Thyroid Neoplasms
Familial medullary thyroid carcinoma
Neoplasm Metastasis
Therapeutics
Genes

Keywords

  • Familial thyroid cancer
  • Family history
  • Thyroid cancer

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Nixon, I. J., Suárez, C., Simo, R., Sanabria, A., Angelos, P., Rinaldo, A., ... Ferlito, A. (2016). The impact of family history on non-medullary thyroid cancer. European Journal of Surgical Oncology, 42(10), 1455-1463. https://doi.org/10.1016/j.ejso.2016.08.006

The impact of family history on non-medullary thyroid cancer. / Nixon, I. J.; Suárez, C.; Simo, R.; Sanabria, A.; Angelos, P.; Rinaldo, A.; Rodrigo, J. P.; Kowalski, L. P.; Hartl, D. M.; Hinni, M. L.; Shah, J. P.; Ferlito, A.

In: European Journal of Surgical Oncology, Vol. 42, No. 10, 01.10.2016, p. 1455-1463.

Research output: Contribution to journalReview article

Nixon, IJ, Suárez, C, Simo, R, Sanabria, A, Angelos, P, Rinaldo, A, Rodrigo, JP, Kowalski, LP, Hartl, DM, Hinni, ML, Shah, JP & Ferlito, A 2016, 'The impact of family history on non-medullary thyroid cancer', European Journal of Surgical Oncology, vol. 42, no. 10, pp. 1455-1463. https://doi.org/10.1016/j.ejso.2016.08.006
Nixon IJ, Suárez C, Simo R, Sanabria A, Angelos P, Rinaldo A et al. The impact of family history on non-medullary thyroid cancer. European Journal of Surgical Oncology. 2016 Oct 1;42(10):1455-1463. https://doi.org/10.1016/j.ejso.2016.08.006
Nixon, I. J. ; Suárez, C. ; Simo, R. ; Sanabria, A. ; Angelos, P. ; Rinaldo, A. ; Rodrigo, J. P. ; Kowalski, L. P. ; Hartl, D. M. ; Hinni, M. L. ; Shah, J. P. ; Ferlito, A. / The impact of family history on non-medullary thyroid cancer. In: European Journal of Surgical Oncology. 2016 ; Vol. 42, No. 10. pp. 1455-1463.
@article{22b8c2efecc54cb49110ccf1567a7fab,
title = "The impact of family history on non-medullary thyroid cancer",
abstract = "Introduction Around 10{\%} of patients with non-medullary thyroid cancer (NMTC) will have a positive family history for the disease. Although many will be sporadic, families where 3 first-degree relatives are affected can be considered to represent true familial non-medullary thyroid cancer (FNMTC). The genetic basis, impact on clinical and pathological features, and overall effect on prognosis are poorly understood. Methods A literature review identified articles which report on genetic, clinical, therapeutic and screening aspects of FNMTC. The results are presented to allow an understanding of the genetic basis and the impact on clinical–pathological features and prognosis in order to inform clinical decision making. Results The genetic basis of FNMTC is unknown. Despite this, significant progress has been made in identifying potential susceptibility genes. The lack of a test for FNMTC has led to a clinical definition requiring a minimum of 3 first-degree relatives to be diagnosed with NMTC. Although some have shown an association with multi-centric disease, younger age and increased rates of extra-thyroidal extension and nodal metastases, these findings are not supported by all. The impact of FNMTC is unclear with all groups reporting good outcome, and some finding an association with more aggressive disease. The role of screening remains controversial. Conclusion FNMTC is rare but can be diagnosed clinically. Its impact on prognostic factors and the subsequent role in influencing management is debated. For those patients who present with otherwise low-risk differentiated thyroid cancer, FNMTC should be included in risk assessment when discussing therapeutic options.",
keywords = "Familial thyroid cancer, Family history, Thyroid cancer",
author = "Nixon, {I. J.} and C. Su{\'a}rez and R. Simo and A. Sanabria and P. Angelos and A. Rinaldo and Rodrigo, {J. P.} and Kowalski, {L. P.} and Hartl, {D. M.} and Hinni, {M. L.} and Shah, {J. P.} and A. Ferlito",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.ejso.2016.08.006",
language = "English (US)",
volume = "42",
pages = "1455--1463",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "10",

}

TY - JOUR

T1 - The impact of family history on non-medullary thyroid cancer

AU - Nixon, I. J.

AU - Suárez, C.

AU - Simo, R.

AU - Sanabria, A.

AU - Angelos, P.

AU - Rinaldo, A.

AU - Rodrigo, J. P.

AU - Kowalski, L. P.

AU - Hartl, D. M.

AU - Hinni, M. L.

AU - Shah, J. P.

AU - Ferlito, A.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Introduction Around 10% of patients with non-medullary thyroid cancer (NMTC) will have a positive family history for the disease. Although many will be sporadic, families where 3 first-degree relatives are affected can be considered to represent true familial non-medullary thyroid cancer (FNMTC). The genetic basis, impact on clinical and pathological features, and overall effect on prognosis are poorly understood. Methods A literature review identified articles which report on genetic, clinical, therapeutic and screening aspects of FNMTC. The results are presented to allow an understanding of the genetic basis and the impact on clinical–pathological features and prognosis in order to inform clinical decision making. Results The genetic basis of FNMTC is unknown. Despite this, significant progress has been made in identifying potential susceptibility genes. The lack of a test for FNMTC has led to a clinical definition requiring a minimum of 3 first-degree relatives to be diagnosed with NMTC. Although some have shown an association with multi-centric disease, younger age and increased rates of extra-thyroidal extension and nodal metastases, these findings are not supported by all. The impact of FNMTC is unclear with all groups reporting good outcome, and some finding an association with more aggressive disease. The role of screening remains controversial. Conclusion FNMTC is rare but can be diagnosed clinically. Its impact on prognostic factors and the subsequent role in influencing management is debated. For those patients who present with otherwise low-risk differentiated thyroid cancer, FNMTC should be included in risk assessment when discussing therapeutic options.

AB - Introduction Around 10% of patients with non-medullary thyroid cancer (NMTC) will have a positive family history for the disease. Although many will be sporadic, families where 3 first-degree relatives are affected can be considered to represent true familial non-medullary thyroid cancer (FNMTC). The genetic basis, impact on clinical and pathological features, and overall effect on prognosis are poorly understood. Methods A literature review identified articles which report on genetic, clinical, therapeutic and screening aspects of FNMTC. The results are presented to allow an understanding of the genetic basis and the impact on clinical–pathological features and prognosis in order to inform clinical decision making. Results The genetic basis of FNMTC is unknown. Despite this, significant progress has been made in identifying potential susceptibility genes. The lack of a test for FNMTC has led to a clinical definition requiring a minimum of 3 first-degree relatives to be diagnosed with NMTC. Although some have shown an association with multi-centric disease, younger age and increased rates of extra-thyroidal extension and nodal metastases, these findings are not supported by all. The impact of FNMTC is unclear with all groups reporting good outcome, and some finding an association with more aggressive disease. The role of screening remains controversial. Conclusion FNMTC is rare but can be diagnosed clinically. Its impact on prognostic factors and the subsequent role in influencing management is debated. For those patients who present with otherwise low-risk differentiated thyroid cancer, FNMTC should be included in risk assessment when discussing therapeutic options.

KW - Familial thyroid cancer

KW - Family history

KW - Thyroid cancer

UR - http://www.scopus.com/inward/record.url?scp=84989967008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989967008&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2016.08.006

DO - 10.1016/j.ejso.2016.08.006

M3 - Review article

VL - 42

SP - 1455

EP - 1463

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 10

ER -